News|Articles|May 23, 2026

Can Multiparametric MRI Enhance Differentiation of Non-Mass Enhancement Breast Lesions?

Author(s)Jeff Hall

In a study of 351 women with BI-RADS 3-5 non-mass enhancement breast lesions, researchers found that multiparametric MRI offered 98.4 percent sensitivity and a 97.9 percent negative predictive value (NPV).

New research affirms the effectiveness of multiparametric MRI (mpMRI) for differentiating BI-RADS 3-5 breast lesions with non-mass enhancement (NME).

For the prospective study, recently reported in European Radiology, researchers reviewed mpMRI data for 351 women (mean age off 44.2) drawn from seven tertiary facilities. All women in the cohort had BI-RADS 3-5 NME presentations with 189 of the lesions being malignant, according to the study. The study authors noted that nine radiologists with 12 to 20 years of breast MRI experience reviewed the images and the study utilized centralized imaging over a 20-month period.

The researchers found that consensus-based mpMRI provided 98.4 percent sensitivity, 86.4 percent specificity and an AUC of 94 percent.

“This prospective study demonstrated that multiparametric MRI combining DCE morphology, kinetics, and ADC measurements significantly enhanced diagnostic performance for indeterminate/suspicious NME lesions compared with individual parameters,” noted lead study author Basma K. Soliman, MD, who is affiliated with the Department of Diagnostic Radiology and the Faculty of Human Medicine at Zagazig University in Zagazig, Egypt, and colleagues.

The study authors also noted that mpMRI offered a 89.4 percent positive predictive value (PPV) as well as a 97.9 negative predictive value (NPV).

“A high NPV (97.9%) suggests that low-risk NMEs can safely undergo short-term follow-up rather than immediate biopsy, potentially reducing unnecessary biopsies by approximately 14%,” posited Soliman and colleagues.

Three Key Takeaways

• mpMRI offers strong diagnostic performance for NME lesions. Consensus-based multiparametric MRI achieved 98.4 percent sensitivity, 86.4 percent specificity, and a 94 percent AUC when evaluating BI-RADS 3–5 non-mass enhancement lesions — outperforming any single imaging parameter alone. Combining DCE morphology, kinetics, and ADC measurements was key to this enhanced accuracy.

• A high NPV supports a "watch and wait" approach for low-risk NME. With a negative predictive value of 97.9 percent, mpMRI can help clinicians confidently defer immediate biopsy in favor of short-term follow-up for lesions that appear low-risk, with the authors estimating this could reduce unnecessary biopsies by approximately 14 percent.

• Specific MRI features are strong independent predictors of malignancy. Multivariable analysis identified several high-risk features clinicians should flag — most notably a type III washout curve (nearly 27× higher likelihood of malignancy) and segmental distribution (over 9× higher likelihood) — findings that can help prioritize which NME lesions warrant urgent workup.

Multivariable analysis revealed five MRI parameters that were statistically significant indicators of malignancy, including:

• a type II plateau curve associated with over a sixfold higher likelihood of malignancy;

• segmental distribution with over a ninefold higher likelihood of malignancy; and

• a type III washout curve, which had a nearly 27-fold higher likelihood of malignancy, according to the study authors.

(Editor’s note: For related content, see “Breast Radiologists Say New ACP Breast Cancer Screening Guidelines are ‘Many Steps Backward’ and ‘Dangerous’,” “New Breast MRI Study Says Background Parenchymal Enhancement Has No Impact on Lesion Detection” and “Breast MRI Study Links Peritumoral Edema to Reduced Disease-Free Survival from Breast Cancer in Young Women.”)

In regard to study limitations, the authors acknowledged the use of one 1.5T MRI system, the potential variability of values from ADC mapping across different field strengths and vendors, and the exclusion of BI-RADS 2 lesions. The study authors also noted that reviewing radiologists were blinded to patient clinical history.


Latest CME